singaporeen
The Value tortoise is on the move

The Value tortoise is on the move

08-12-2020 | Monthly outlook
The availability of an effective Covid-19 vaccine may trigger a revival for Value investing, says Robeco strategist Peter van der Welle.
  • Peter van der Welle
    Peter
    van der Welle
    Strategist Global Macro team

Speed read

  • Value stocks have outperformed since vaccine news broke
  • Three factors support Value as economic normality returns
  • Rally might be catch-up rather than full rotation in near term

He says approved vaccines make it possible for the world to return to normal, favoring the more cyclical and lockdown-hit stocks that have so far suffered during the pandemic.

Value stocks are companies whose share prices do not match the perceived underlying potential of the business, offering upside. The style has underperformed growth investing, which favors high-growth industries such as technology, for more than a decade.

“November saw big moves in markets as the announcement of several Covid-19 vaccines with a high effectiveness handed the keys to the resolution of a pandemic that has brought the deepest recession since the 1930s,” says Van der Welle, strategist with Robeco’s multi-asset team.

Stay informed on our latest insights with monthly mail updates
Stay informed on our latest insights with monthly mail updates
Subscribe
The performance of growth stocks versus value stocks this year. Source: Refinitiv Datastream, Robeco

“Stock market indices broke new highs, with the largest inflows into equities in recorded history in recent weeks. November saw a decent outperformance of value stocks versus growth stocks of close to 5%. Value stocks that have been lagging the recovery trade since March have experienced a rerating since the vaccine news broke in November.”

“This catch-up has raised the question of whether the long-awaited rotation from growth to value has finally begun – the jury is still out on this. In November, value stocks jolted 15% higher, but tech stocks also rose substantially, gaining 10.9%.”

“We think that the announcement of several effective vaccines and nascent approval for one of them in the UK has nonetheless brought the value tortoise on the move, with further upside for value stock outperformance seen in 2021.”

Value is exceptionally cheap

One market dynamic is that after so many months of being downtrodden during the pandemic, value stocks have become exceptionally cheap relative to their growth stock counterparts.

“Valuations are not always a useful tool for tactical asset allocation and are rarely an autonomous trigger,” says Van der Welle. “And in the value versus growth debate, there might be good reasons to think that tech stocks are on a secular uptrend, and therefore deserve to trade at a higher multiple. The Covid-19 pandemic and its aftermath have accelerated the digital transformation thesis that benefits growth stocks.”

“Yet, with a relative price/earnings multiple of around 2, the dispersion between value and growth valuations has become exceptional, and it suggests the value factor will see returns above the historical average in the medium to longer term, outperforming growth stocks.”

Three factors favor Value

So, has the value in value been finally unlocked? Van der Welle says three arguments favor the theory that value is back. “First, value has the tendency to outperform at the beginning of a new economic cycle,” he says. “While our business cycle model still signals an economic slowdown, we expect it to go into a flash ‘recovery’ soon.”

“At the end of recessions, yield curves in the bond markets start to steepen, as bond investors start to demand a higher compensation for growth risk in the market. Value stocks have tended in the past to rebound relative to growth stocks, as yield curves steepened further in the early recovery phase.”

The second favorable factor is the absence of ’economic growth scarcity’ as the world emerges from the pandemic. “Growth stocks have shown a strong multiple expansion in recent years, as investors were willing to pay up for companies with cashflow generation ability in a late-cycle, growth-scarce environment,” Van der Welle says. “This accelerated when the Covid-19 recession peaked in March. With economic growth scarcity now on the verge of fading, a headwind for value stocks disappears.”

Government intervention helps

Finally, Van der Welle says governments have shown a greater willingness to provide fiscal support during this pandemic, in sharp contrast with the global financial crisis aftermath, when governments were even pursuing austerity.

“This accommodative fiscal stance, facilitated by central banks acting as credible fiscal financiers, has two major implications for the value trade,” he says. “First, higher net government issuance as a consequence of fiscal easing exerts upward pressure on bond yields, which benefits the less interest rate-sensitive segments of the equity universe such as value stocks.”

“Second, if government spending is effective, there are positive multiplier effects on the real economy, which benefits more growth-sensitive stocks like value stocks.”

Catch-up or rotation?

However, Van der Welle cautions against getting too carried away. “The recent outperformance of value stocks could predominantly be because they are catching up rather than due to a rotation,” he says.

“Investors didn’t dump growth stocks in November, so the November market action should not be prejudged as a great rotation out of growth to value. The big winners in November were the stocks that suffered the most because of the pandemic, and were simply laggards since the March bull run.”

“Looking ahead, the improved outlook for hospitality and leisure in the wake of a vaccine will also indirectly benefit growth stocks through things such as higher advertising revenues from hotels and restaurants on digital platforms. The digital transformation of the global economy will remain a secular tailwind for growth stocks.”

“In addition, the steep rise in Covid-19 cases, a volatile US presidential power transition, and a spat between the US Treasury and the Fed, which is hampering coordination between fiscal and monetary policy, are key near-term risks for value.”

Beating the virus

It all boils down to beating Covid-19. “With inoculations due to begin this month in a few major economies, the trilemma between solving the health crisis, kick-starting economic growth and maintaining personal freedoms is going to be considerably eased,” he says.

“The case for additional value outperformance in the next 12 months is strengthening. But we are not out of the woods yet. The road to a post-Covid-19 ‘new normal’ will not be smooth, which implies selective exposure towards the value tilt against a backdrop of near-term risks. The value tortoise may have made some promising moves lately, but it has yet to bridge a soft patch.”

Important information

This information is for informational purposes only and should not be construed as an offer to sell or an invitation to buy any securities or products, nor as investment advice or recommendation.
The contents of this document have not been reviewed by the Monetary Authority of Singapore (“MAS”). Robeco Singapore Private Limited holds a capital markets services license for fund management issued by the MAS and is subject to certain clientele restrictions under such license.
An investment will involve a high degree of risk, and you should consider carefully whether an investment is suitable for you.

Logo

Important Information

Warning/Important note: This website contains information which is only available to qualified investors as defined below. If you are not a qualified investor, please click “I Disagree” to leave the website.

By clicking on "I agree", I declare that: 

  • I am a qualified investor as defined under 1
  • I have read and understood the Terms and Conditions and Disclaimers as described under 2

1 - This website may only be accessed directly or indirectly by the following persons in Singapore:

1) “institutional investor” under section 304 of the Securities and Futures Act (Cap.289)(“SFA”), which means:
(i) the Government; (ii) a statutory board as may be prescribed by regulations made under section 341 of the SFA; (iii) an entity that is wholly and beneficially owned, whether directly or indirectly, by a central government of a country and whose principal activity is (A) to manage its own funds; (B) to manage the funds of the central government of that country (which may include the reserves of that central government and any pension or provident fund of that country); or (C) to manage the funds (which may include the reserves of that central government and any pension or provident fund of that country) of another entity that is wholly and beneficially owned, whether directly or indirectly, by the central government of that country; (iv) any entity (A) that is wholly and beneficially owned, whether directly or indirectly, by the central government of a country; and (B) whose funds are managed by an entity mentioned in sub-paragraph (iii); (v) a central bank in a jurisdiction other than Singapore; (vi) a central government in a country other than Singapore; (vii) an agency (of a central government in a country other than Singapore) that is incorporated or established in a country other than Singapore; (viii) a multilateral agency, international organisation or supranational agency as may be prescribed by regulations made under section 341 of the SFA; (ix) a bank that is licensed under the Banking Act (Cap.19); (x) a merchant bank that is approved as a financial institution under section 28 of the Monetary Authority of Singapore Act (Cap.186); (xi) a finance company that is licensed under the Finance Companies Act (Cap.108); (xii) a company or co-operative society that is licensed under the Insurance Act (Cap.142) to carry on insurance business in Singapore; (xiii) a company licensed under the Trust Companies Act (Cap.336); (xiv) a holder of a capital markets services licence; (xv) an approved exchange; (xvi) a recognised market operator; (xvii) an approved clearing house; (xviii) a recognised clearing house; (xix) a licensed trade repository; (xx) a licensed foreign trade repository; (xxi) an approved holding company; (xxii) a Depository as defined in section 81SF of the SFA; (xxiii) an entity or a trust formed or incorporated in a jurisdiction other than Singapore, which is regulated for the carrying on of any financial activity in that jurisdiction by a public authority of that jurisdiction that exercises a function that corresponds to a regulatory function of the Authority under this Act, the Banking Act (Cap.19), the Finance Companies Act (Cap.108), the Monetary Authority of Singapore Act (Cap.186), the Insurance Act (Cap.142), the Trust Companies Act (Cap.336) or such other Act as may be prescribed by regulations made under section 341 of the SFA; (xxiv) a pension fund, or collective investment scheme, whether constituted in Singapore or elsewhere; (xxv) a person (other than an individual) who carries on the business of dealing in bonds with accredited investors or expert investors; (xxvi) the trustee of such trust as the Authority may prescribe, when acting in that capacity; or; (xxvii) such other person as the Authority may prescribe.

2) “relevant person” under section 305(1) of the SFA, which means:
(i) An accredited investor; (ii) a corporation the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; (iii) a trustee of a trust the sole purpose of which is to hold investments and each beneficiary of which is an individual who is an accredited investor; (iv) an officer or equivalent person of the person making the offer (such person being an entity) or a spouse, parent, brother, sister, son or daughter of that officer or equivalent person; or (v) a spouse, parent, brother, sister, son or daughter of the person making the offer (such person being an individual).

3) any person who acquires the units [in a collective investment scheme] as principal if the offer is on terms that the units may only be required at a consideration of not less than $200,000 (or its equivalent in a foreign currency) for each transaction, whether such amount is to be paid for in cash or by exchange of units in a collective investment scheme, securities, securities-based derivatives contracts or other assets, and if the following condition is satisfied: (i) the offer is not accompanied by an advertisement making an offer or calling attention to the offer or intended offer; (ii) no selling or promotional expenses are paid or incurred in connection with the offer other than those incurred for administrative or professional services, or by way of commission or fee for services rendered by any of the persons specified in section 302B(1)(d)(i) to (vi) of the SFA; and (iii) no prospectus in respect of the offer has been registered by the Authority or, where a prospectus has been registered (A) the prospectus has eAccxpired pursuant to section 299 of the SFA; or (B) the person making the offer has before making the offer 1. informed the Authority by notice in writing of its intent to make the offer in reliance on the exemption under this subsection; and 2. taken reasonable steps to inform in writing the person to whom the offer is made that the offer is made in reliance on the exemption under this subsection.

4) Or otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.

If you are not any of the types of persons described above, you are not authorized to enter this website and you should leave this website immediately.

2 Terms and Conditions
You acknowledge that you have read these Terms and Conditions (“Terms”) prior to accessing the website located at www.robeco.com/sg (“Website”) and you agree to be bound by the Terms.  If you do not agree to all of the Terms, you are not an authorised user and you should not use the Website. The Website is owned by Robeco Singapore Private Limited (company registration number: UEN. 201541306Z), which is licensed by the Monetary Authority of Singapore (“MAS”) pursuant to the Securities and Futures Act (Cap.289) (“SFA”) of Singapore, and is managed by Robeco Singapore Private Limited and/or its affiliates (collectively, as “Robeco”). The Website is intended for and should be accessed by institutional investors or accredited investors (as defined under Section 4A of the SFA) of Singapore.  The Website is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject the Robeco to any registration or licensing requirement within such jurisdiction.  It is your responsibility to observe all applicable laws, rules and regulations of any relevant jurisdiction. The content contained in the Website is owned by Robeco and/or its information providers and is protected by applicable copyrights, trademarks, service marks, and/or other intellectual property rights.  You may not copy, distribute, modify, post, frame or link the Website, including any text, graphics, video, audio, software code, user interface, design or logos.  You may not distribute, modify, transmit, reuse, repost, or use the content of the Website for public or commercial use, including all text, images, audio and/or video.  Robeco may terminate your access to the Website for any reason, without prior notice. Neither Robeco, nor any of its associates, nor any director, officer or employee accepts any liability whatsoever for any loss arising directly or indirectly from the access of the Website.  You agree to indemnity and hold Robeco, its associates, directors, officers or employees harmless against any and all claims, losses, liability, costs and expenses arising from your use of the Website due to violation of the Terms. Robeco reserves the right to change, modify, add or remove any parts of the Terms at any time and for any reason.  The Terms shall deemed to be effective immediately upon posting. The Terms shall be governed by, and shall be construed in accordance with, the law of Singapore.

Disclaimers
The Website has not been reviewed by the MAS. Accordingly, the Website may not be accessed directly or indirectly to persons in Singapore other than (i) to an institutional investor under Section 304 of the SFA, (ii) to a relevant person pursuant to Section 305(1), or any person pursuant to Section 305(2), and in accordance with the conditions specified in Section 305, of the SFA, or (iii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. 

Nothing in the Website constitutes tax, accounting, regulatory, legal or investment advice.  The Website is for informational purposes only and should not be construed as an offer to sell or an invitation to buy any securities or products, nor as investment advice or recommendation or for the purpose of soliciting any action in relation to Robeco’s businesses, or solicitation by anyone in any jurisdiction in which such an offer or solicitation is not authorised or to any person to whom it is unlawful to make such an offer and solicitation. Any reproduction or distribution of information from the Website, in whole or in part, or the disclosure of its contents, without the prior written consent of Robeco, is prohibited.  By accessing to the Website, you agree to the foregoing.  

The funds referred to in the Website are for information only.  It is not a recommendation or investment advice, nor does it mean the funds is suitable for all investors.  The contents of the website is not reviewed by the MAS.  Any decision to participate in the funds should be made only after reviewing the sections regarding investment considerations, conflicts of interest, risk factors and the relevant Singapore selling restrictions.  You should consult your professional adviser if you are in doubt about the stringent restrictions applicable to the use of the Website, regulatory status of the funds, applicable regulatory protection, associated risks and suitability of the funds to your objectives.

Any decisions made based on the information contained in the Website are the sole responsibility of yours.  Any investments made or to be made shall be with your independent analyses based on your financial situation and objectives.  The investments and strategies contained in the Website may not be suitable for all investors and are not guaranteed by Robeco.  

Investment involves risks and may lose value.  Historical returns are provided for illustrative purposes only and do not necessarily reflect Robeco’s expectations for the future.  The value of your investments may fluctuate.  Past performance is no indication of current or future performance.  The Website may contain projections or other forward looking statements regarding future events or future financial performance of countries, markets or companies and such projection or forecast is not indicative of the future.  The information contained in the Website, including any data, projections and underlying assumptions are based upon certain assumptions, management forecasts and analysis of information available on an “as is” basis and without warranties of any kind, whether express or implied, and reflects prevailing conditions and Robeco’s views as of the date published or indicated, and maybe superseded by subsequent events or for other reasons.  The information contained in the Website are accordingly subject to change at any time without notice and Robeco are under no obligation to notify you of any of these changes.  Robeco expressly disclaims all liability for errors and omissions in the information presented in the Website and for the use or interpretation by others of information contained in the Website.

Robeco Singapore Private Limited holds a capital markets services licence for fund management issued by the MAS and is subject to certain clientele restrictions under such licence.  An investment will involve a high degree of risk, and you should consider carefully whether an investment is suitable for you.

I Disagree